## **Core Concept**
Glycogen storage diseases (GSDs) are a group of inherited disorders caused by enzyme deficiencies that affect glycogen synthesis or breakdown. These disorders result in abnormal glycogen accumulation or depletion in various tissues, leading to a range of clinical manifestations. Enzyme replacement therapy (ERT) is a treatment approach used for certain GSDs.

## **Why the Correct Answer is Right**
The correct answer, **Pompe disease (GSD II)**, is a lysosomal storage disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). This enzyme is necessary for the breakdown of glycogen within lysosomes. Without it, glycogen accumulates in lysosomes, particularly affecting muscle cells. ERT for Pompe disease involves administering recombinant human GAA to patients, which helps to reduce glycogen accumulation and improve muscle function.

## **Why Each Wrong Option is Incorrect**
- **Option A: GSD I (Von Gierke disease)** is caused by glucose-6-phosphatase deficiency. While treatments like dietary management and diazoxide are used, ERT is not the primary treatment approach.
- **Option B: GSD III (Cori disease)** results from debranching enzyme deficiency. Management includes dietary adjustments and liver transplantation in some cases, but ERT is not standard.
- **Option C: GSD IV (Andersen disease)** is due to branching enzyme deficiency. Treatment focuses on supportive care and, in some cases, liver transplantation, but ERT is not commonly used.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that Pompe disease is unique among GSDs in that it has a specific and effective treatment option: enzyme replacement therapy with recombinant human acid alpha-glucosidase. Early diagnosis and initiation of ERT can significantly improve outcomes in affected patients.

## **Correct Answer:** D. Pompe disease.